PERSONAL INFORMATION

Marta Cipriani

✉ marta.cipriani@uniroma1.it

WORK EXPERIENCE

June 2002 – Present — ### Biostatistical consultant
Fondazione GIMEMA Franco Mandelli ONLUS

Feb 2002 – May 2002 — ### Research collaborator
Fondazione GIMEMA Franco Mandelli ONLUS

May 2021 – Dec 2021 — ### Fellow
Sapienza University of Rome

EDUCATION AND TRAINING

2024–Present — ### Ph.D. in Mathematics
Leiden University
Supervisor: Prof. Marta Fiocco

2022–Present — ### Ph.D. in Methodological Statistics
Sapienza University of Rome
Supervisor: Prof. Marco Alfò

May 2022 — ### M.Sc. in Statistical Science - Major: Biostatistics
Sapienza University of Rome
Thesis title: *"Modelli congiunti e pseudo-osservazioni in analisi di sopravvivenza"*.
Final vote: 110/110 cum laude.
Supervisor: Prof. Marco Alfò

July 2019 — ### B.Sc. in Political Sciences
Roma Tre University
Thesis title: *"Il modello di Cox applicato ad un'indagine su salute e longevità in Cina"*.
Final vote: 110/110 cum laude.
Supervisor: Prof. Francesco Lagona

July 2016 — ### ESABAC Double High School Diploma
Liceo Classico Virgilio, Rome, Italy - Académie de Nice.
Final vote: 100/100

RESEARCH VISITS

March 2024–Present — ### Ph.D. visiting
University of Leiden, Netherlands

September 2018–February 2019 — ### Erasmus+ Program
University Paris I Panthéon-Sorbonne, Paris, France

AWARDS, GRANTS & SCHOLARSHIP

November 2023 — Research Grant for Junior Researcher, "Avvio alla ricerca"
Sapienza University of Rome
Principal Investigator. Project title: Unlocking the Potential of Artificial Intelligence for Generating Synthetic Patients in Clinical Trials

November 2022 — Scholarship
Sapienza University of Rome
Ph.D. School of Statistical Science
Three years of Ph.D. scholarship

TEACHING EXPERIENCE

September 2023–February 2024 — Teaching Assistant
Department of Statistical Science, Sapienza University of Rome
Statistica di base, Prof. Valeria Sambucini

September 2023–February 2024 — Teaching Assistant
Department of Political Science, Roma Tre University
Statistica, Prof. Francesco Lagona

PERSONAL SKILLS

Mother tongue — Italian

Other languages

	UNDERSTANDING		SPEAKING		WRITING
	Listening	Reading	Spoken interaction	Spoken production	
English	C1	C1	C1	C1	C1
French	C1	C1	C1	C1	C1
	Diplôme du Baccalauréat général				
Spanaish	B1	B1	B1	B1	B1

Levels: A1 and A2: Basic user – B1 and B2: Independent user – C1 and C2: Proficient user
Common European Framework of Reference for Languages

Computer skills
– competent with most Microsoft Office programmes
– advanced user of R and LaTeX
– experience with SAS

PUBLICATIONS

2024   Piciocchi A, Cipriani M *et al.*. Unlocking the potential of synthetic patients for accelerating clinical trials: Results of the first GIMEMA experience on acute myeloid leukemia patients. *eJHaem* (2024)

2023   Lombardo FL, Spila Alegiani S, Mayer F, Cipriani M *et al.*. A randomized double-blind clinical trial on safety and efficacy of tauroursodeoxycholic acid (TUDCA) as add-on treatment in patients affected by amyotrophic lateral sclerosis (ALS): the statistical analysis plan of TUDCA-ALS trial. *Trials* 24, 792 (2023)

2023   Piciocchi A, Chiaretti S, Cipriani M *et al.* A Propensity Score Weighting Analysis Emphasizes the Progress of the Gimema Approach in Adult Ph-Positive Acute Lymphoblastic Leukemia in the TKI Era. *Blood* (2023) 142 (Supplement 1)

2023   Attardi E, Savi A, Borsellino B, Cipriani M *et al.* Unraveling the Impact of 2022 Classifications on Secondary Acute Myeloid Leukemia: Assessing the True Qualification Power of Diagnostic Qualifiers. *Blood* (2023) 142 (Supplement 1)

2023 Cipriani M, Pichiorri F, Colamarino E *et al.* The Promotoer, a brain-computer interface-assisted intervention to promote upper limb functional motor recovery after stroke: a statistical analysis plan for a randomized controlled trial. *Trials* 24, 736 (2023)

2023 Attardi E, Savi A, Borsellino B, Piciocchi A, Cipriani M *et al.*. P499: Applicability of 2022 classifications of acute myeloid leukemia in the real-world setting. *Hemasphere* (2023) 7(Suppl): e5402602

2023 Piciocchi A, Marconi G, Cipriani M *et al.* P523: The comparison of VFLAI, FLAI and 3+7 regimens by multilevel propensity score weighting highlights the benefit of the addition of venetoclax in no low-risk AML treated in GIMEMA trials and real world. *Hemasphere* (2023) 7(Suppl): e0034216

2023 Piciocchi A, Cipriani M *et al.* P495: Unlocking the potential of synthetic patients for accelerating clinical trials: results of the first GIMEMA experience. *Hemasphere* (2023) 7(Suppl): e4536536

2023 Efficace F, Mahon FX, Richter J, Piciocchi A, Cipriani M *et al.* S159: Health-related quality of life of patients with chronic myeloid leukemia after discontinuation of tyrosine kinase inhibitors: results from the EURO-SKI study. *Hemasphere* (2023) 7(Suppl): e0972454

2023 Attardi E, Savi A, Borsellino B, Piciocchi A, Cipriani M *et al.* Applicability of 2022 classifications of acute myeloid leukemia in the real-world setting. *Blood Advances* (2023) 7 (17): 5122–5131.

2023 Martinelli G, Cipriani M, Marconi G, Guolo F *et al.* Addition of venetoclax to FLAI induction chemotherapy (VFLAI) improves survival in patients with intermediate and high-risk AML vs FLAI and 3+7: A GIMEMA Italian cooperative analysis. *Journal of Clinical Oncology* (2023) 41 (16 suppl): 7013-7013.

2023 Cipriani M, Piciocchi A, Arena V, Alfò M. Pseudo-observations in survival analysis. *Book of short papers SIS 2023*: 590-594.

2022 Piciocchi A, Messina M, Cipriani M *et al.* The Addition of Venetoclax to Induction Chemotherapy in No Low-Risk AML Patients: A Propensity Score-Matched Analysis of the Gimema AML1718 and AML1310 Trials. *Blood* (2022) 140 (Supplement 1): 137–138.

2022 Tadesse F, Gebremedhin A, Abubeker A, Piciocchi A, Cipriani M *et al.* Health-Related Quality of Life and Financial Burden of Ethiopian Patients with Chronic Myeloid Leukemia Receiving Tyrosine Kinase Inhibitors. *Blood* (2022) 140 (Supplement 1): 5264–5265.